Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomized clinical trial

Depression
Written By Rob Mudge, M.A.
Psilocybin To Treat Major Depressive Disorder (Placebo-Controlled, Double Blind)

Study

Double-blind, randomized clinical trial with 52 participants with major depressive disorder either received a single, moderate dose of psilocybin or a placebo, plus psychotherapy in both cases.

Results

Results showed a significant clinical and statistical decrease in depressive symptoms for at least two weeks, with 54% of participants in the psilocybin group meeting remission criteria (i.e. no longer had depression).

Discussion

Single experiences with psilocybin coupled with therapy could be effective for treating major depression.

Citation

von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2022). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 56, 101809. doi:10.1016/j.eclinm.2022.101809

Link To Study

Rob Mudge, M.A.

Rob is a psychedelic therapist and integration coach who holds a Masters in Counseling Psychology from Boston College.

Previous

Single-Dose Psilocybin Treatment for Major Depressive Disorder